Fred Ehrsam
Co-Founder @ Paradigm
San Francisco, United States
Fred Ehrsam is a seed investor at Paradigm in San Francisco focused on Blockchain and Cryptocurrency. Fred Ehrsam is the Co-Founder of Paradigm.
- Total investments:
- 56
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Fred Ehrsam invests in
Stages Fred Ehrsam invests in
Countries Fred Ehrsam invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1M–$15M
- Series A
- $7M–$70M
- Series C
- $65M–$300M
Investment Focus
Industry
- Blockchain 15 (27%)
- Cryptocurrency 13 (23%)
- Software 11 (20%)
- Artificial Intelligence 9 (16%)
- Financial Services 8 (14%)
Stage
- Seed 20 (36%)
- Series A 17 (30%)
- Series C 5 (9%)
- Venture - Series Unknown 4 (7%)
- Series B 3 (5%)
Country
- United States 40 (71%)
- Canada 1 (2%)
- Israel 1 (2%)
- Poland 1 (2%)
- Cayman Islands 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Pilgrim
|
Pioneering a biologically enhanced future for humanity. | $25M / Seed / Sep 23, 2026 | |
| Arcadia Medicine is a biotechnology company that creates psychedelic medicine to treat mental health issues. | $9.3M / Seed / Oct 06, 2025 | ||
| Poke is an artificial intelligence assistant that functions as a single iMessage thread that links to files, calendars, and emails before acting. | $15M / Seed / Sep 08, 2025 | ||
| Chai Discovery creates Chai-1, a multi-modal foundation model designed for predicting molecular structures relevant to drug discovery. The model facilitates the unified prediction of proteins, small molecules, and nucleic acids, and is available for free for commercial applications. By enabling accurate predictions without the need for multiplesequence alignments, Chai-1 advances the capabilities of molecular modeling in the life sciences. | $70M / Series A / Aug 06, 2025 | ||
| NewLimit specializes in treating age-related diseases to extend the human health span. It works on developing epigenetic reprogramming medicines to treat diseases with large unmet needs. | $130M / Series B / May 06, 2025 | ||
| Inventex is a patent filling platform that help the businesses for filing application process without any hassle. | $2.4M / Pre-Seed / Apr 10, 2025 | ||
| Dot Product is an AI based firm that offers voice agents that automates operations tasks and deliver reliable customer support. | $6M / Seed / Jan 01, 2025 | ||
| Swift Solar is a company focused on developing advanced solar technology. The company's core innovation is perovskite solar cells, designed to be more efficient and affordable than traditional solar panels. Swift Solar emphasizes domestic manufacturing and abundant raw materials to ensure scalability. | $27M / Series A / Jun 12, 2024 | ||
| Cognition develops artificial intelligence systems for software engineering and code automation. The company operates Devin, an AI software engineer that plans, writes, tests, debugs, and deploys code through integrated development workflows. Its platform works with existing development tools and codebases to support engineering tasks acrossapplication development, maintenance, and issue resolution. Cognition also provides tools that assist teams with system design, technical workflows, and collaborative coding processes. The company focuses on AI agents that automate repetitive engineering work while supporting software teams in managing complex development tasks. | $21M / Series A / Mar 12, 2024 | ||
| NewLimit specializes in treating age-related diseases to extend the human health span. It works on developing epigenetic reprogramming medicines to treat diseases with large unmet needs. | $72.2M / Series A / May 16, 2023 | ||
| See all 56 investments → | |||
Co-Investors
About Paradigm
Paradigm is a research-driven crypto investment firm that funds companies and protocols from their earliest stages. The firm engages in software development, including open-source projects, to contribute to advancements in cryptocurrency, finance, and internet infrastructure. Research is central to its approach, emphasizing technical depth andpractical innovation. In addition to investment, Paradigm collaborates on research, software development, and strategic guidance to support the growth of the crypto ecosystem.
Paradigm Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jackson Dahl
Entrepreneur In Residence
|
|||
Alana Palmedo
Managing Partner and COO
|
|||
Arjun Balaji
Investment Partner
|
|||
Caitlin Pintavorn
Investment partner
|
|||
Casey Caruso
Investment Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Fred Ehrsam invest in?
Fred Ehrsam invests primarily in Blockchain, Cryptocurrency and Software startups, most often at Seed and Series A stage. Most of the 56 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Fred Ehrsam's check size?
Fred Ehrsam typically joins rounds of $1M–$15M at Seed, $7M–$70M at Series A and $65M–$300M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Fred Ehrsam participates in.
How do I contact Fred Ehrsam?
Public channels for Fred Ehrsam include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Fred Ehrsam last invest?
The most recent investment recorded for Fred Ehrsam closed in Sep 2026. Shizune tracks 56 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
